Exhibit 1.1 ----------- JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G/A, dated Febraury 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, $.01 par value, of Bio- Technology General Corp....Joint Filing Agreement • February 14th, 2003 • Bio Technology General Corp • Medicinal chemicals & botanical products
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated Febraury 14, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, $.01 par value, of Bio-Technology General Corp. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Exhibit 10(bb) EMPLOYMENT AGREEMENT AGREEMENT made as of January 23, 2000, among BIO-TECHNOLOGY GENERAL CORP., a Delaware corporation with an office at 70 Wood Avenue South, Iselin, New Jersey 08830 ("BTG"), BIO-TECHNOLOGY GENERAL (ISRAEL) LTD., an...Employment Agreement • March 30th, 2000 • Bio Technology General Corp • Medicinal chemicals & botanical products • New Jersey
EMPLOYMENT AGREEMENT AGREEMENT made as of April 27, 1999, between BIO- TECHNOLOGY GENERAL CORP., a Delaware corporation with an office at 70 Wood Avenue South, Iselin, New Jersey 08830 (the "Company") and Virgil Thompson, residing at...Employment Agreement • May 17th, 1999 • Bio Technology General Corp • Medicinal chemicals & botanical products • New Jersey
SAVIENT PHARMACEUTICALS, INC. 4,300,000 Shares of Common Stock, $.01 per share par value Underwriting AgreementSavient Pharmaceuticals Inc • October 9th, 2009 • Medicinal chemicals & botanical products • New York
Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 4,300,000 shares of Common Stock, $.01 per share par value (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 645,000 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
SAVIENT PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of February 4, 2011 4.75% Convertible Senior Notes due 2018Indenture • February 4th, 2011 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
INDENTURE dated as of February 4, 2011 between SAVIENT PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
EMPLOYMENT AGREEMENT FOR LAWRENCE A. GYENES SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASUREREmployment Agreement • August 27th, 2004 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New Jersey
RIGHTS AGREEMENT between Savient Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC, as Rights Agent Dated August 6, 2012Rights Agreement • August 7th, 2012 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • Delaware
RIGHTS AGREEMENT, dated August 6, 2012 (the “Agreement”), between Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability company, as Rights Agent (the “Rights Agent”).
Exhibit ff FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT This Amendment dated as of June 9, 1999 by and between Bio-Technology General Corp., a Delaware corporation (the "Company"), and Virgil Thompson (the "Executive") to the Employment Agreement (the...Employment Agreement • March 30th, 2000 • Bio Technology General Corp • Medicinal chemicals & botanical products
AGREEMENT ANDAgreement and Plan of Reorganization • March 30th, 2001 • Bio Technology General Corp • Medicinal chemicals & botanical products • New York
Exhibit 10.1 EMPLOYMENT AGREEMENT AGREEMENT made as of March 14, 2001, between BIO-TECHNOLOGY GENERAL CORP., a Delaware corporation with an office at 70 Wood Avenue South, Iselin, New Jersey 08830 (the "Company") and Bernard R. Tyrrell, having a...Employment Agreement • May 15th, 2001 • Bio Technology General Corp • Medicinal chemicals & botanical products • New Jersey
INTRODUCTIONAsset Purchase Agreement • March 24th, 2005 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
EMPLOYMENT AGREEMENT AGREEMENT made as of July 23, 1999, between BIO-TECHNOLOGY GENERAL CORP., a Delaware corporation with an office at 70 Wood Avenue South, Iselin, New Jersey 08830 (the "Company"), and Robert M. Shaw, having a residence at 17...Employment Agreement • August 13th, 1999 • Bio Technology General Corp • Medicinal chemicals & botanical products • New Jersey
SAVIENT PHARMACEUTICALS, INC. COPROMOTION AGREEMENTEntire Agreement • March 24th, 2005 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
ANDRights Agreement • October 9th, 1998 • Bio Technology General Corp • Medicinal chemicals & botanical products • Delaware
EXHIBIT 2.1 SHARE PURCHASE AGREEMENTShare Purchase Agreement • March 24th, 2005 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
SAVIENT PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT FOR PAUL HAMELIN SENIOR VICE PRESIDENT – COMMERCIAL OPERATIONSEmployment Agreement • May 25th, 2006 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New Jersey
This Agreement is made, entered into, and is effective as of the Effective Date, by and between the Company and the Executive.
EMPLOYMENT AGREEMENTEmployment Agreement • September 27th, 2012 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New Jersey
This Agreement is made, entered into, and is effective as of the Effective Date, by and between the Company and the Executive.
5,927,343 Units SAVIENT PHARMACEUTICALS, INC. PLACEMENT AGENT AGREEMENTSavient Pharmaceuticals Inc • April 3rd, 2009 • Medicinal chemicals & botanical products • New York
SAVIENT PHARMACEUTICALS, INC. [—]% Convertible Senior Notes due [February 1], 20[18] Underwriting AgreementSavient Pharmaceuticals Inc • January 31st, 2011 • Medicinal chemicals & botanical products • New York
Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $[125,000,000] principal amount of its [—]% Convertible Senior Notes due 20[18] (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $[18,750,000] principal amount of its [—]% Convertible Senior Notes due 20[18] (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such [—]% Convertible Senior Notes due 20[18] granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per share (the “Common Stock”). The Securities will be issued p
OFFICE LEASE AGREEMENT BY AND BETWEEN WELLS REIT – MULTI-STATE OWNER, LLC AND SAVIENT PHARMACEUTICALS, INC. Bridgewater Crossing 400 Crossing Boulevard Bridgewater, New JerseyOffice Lease Agreement • February 29th, 2012 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products
THIS OFFICE LEASE AGREEMENT (this “Lease”) is dated as of the 23rd day of January, 2012, by and between WELLS REIT – MULTI-STATE OWNER, LLC, a Delaware limited liability company (“Landlord”), and SAVIENT PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
LEASE AND LEASE AGREEMENT Between SCV Partners The Landlord And Bio-Technology General Corp. The Tenant For Leased Premises In One Tower Center East Brunswick, New Jersey June 11, 2002Lease and Lease Agreement • November 15th, 2002 • Bio Technology General Corp • Medicinal chemicals & botanical products • New Jersey
LEASE AND LEASE AGREEMENT, dated as of June 11, 2002, between SCV Partners, a New Jersey general partnership, with offices c/o Boston Properties at 302 Carnegie Center, Princeton, New Jersey 08540 (the “Landlord”), and Bio-Technology General Corp., a Delaware corporation, with its principal office at 70 Wood Avenue South, Iselin, New Jersey 08830 (the “Tenant”).
Amendment to Employment AgreementAmendment to Employment Agreement • March 2nd, 2009 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products
STOCK OPTION AGREEMENT (Non-Qualified Stock Option to Employee)Stock Option Agreement • October 9th, 2012 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • Delaware
NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) made as of September 24, 2012, between SAVIENT PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and John P. Hamill, an employee of the Company or of a subsidiary of the Company (the “Optionee”).
EXCHANGE AND PURCHASE AGREEMENTExchange and Purchase Agreement • May 9th, 2012 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products
(including any other persons or entities exchanging Existing Notes (as defined below) or purchasing New Notes (as defined below) hereunder for whom the undersigned Holder holds contractual and investment authority, the “Holder”) enters into this Exchange and Purchase Agreement (the “Agreement”) with Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on May 7, 2012 whereby the Holder will (a) exchange (the “Exchange”) certain of the Company’s 4.75% Convertible Senior Notes due 2018 (the “Existing Notes”) for certain of the Company’s Units (as defined below), each Unit consisting of (i) $1,000 principal amount at maturity new Senior Secured Discount Notes due 2019 (the “New Notes”) that will be issued pursuant to the provisions of an Indenture, to be dated as of May 9, 2012 in the form of Exhibit A hereto (the “Indenture”) between the Company, each of the guarantors named therein (the “Guarantors”) and U.S. Bank National Association, as Trustee (the “Trustee”) and col
SUPPLY AGREEMENT Dated: Wednesday, May 23, 2007 between SAVIENT Pharmaceuticals, Inc., and NOF CORPORATIONSupply Agreement • February 10th, 2009 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products
This SUPPLY AGREEMENT (“Agreement”) is made and entered into on the 23rd day of May, 2007 by and between SAVIENT Pharmaceuticals, Inc., a Delaware corporation whose registered office is at One Tower Center, 14th Floor, East Brunswick, NJ 08816, U.S.A. (“SAVIENT”), and NOF CORPORATION, a corporation duly organized under the laws of Japan, located at 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo, 150-6019, Japan (“NOF”),
ACQUISITION AGREEMENT among SAVIENT PHARMACEUTICALS, INC. AND SAVIENT PHARMA HOLDINGS, INC., as Sellers, and CREALTA PHARMACEUTICALS LLC as Purchaser Dated as of December 10, 2013Acquisition Agreement • December 16th, 2013 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • Delaware
THIS ACQUISITION AGREEMENT, dated as of December 10, 2013 (this “Agreement”), is made among Savient Pharmaceuticals, Inc., a Delaware corporation (the “Parent”), its wholly-owned subsidiary, Savient Pharma Holdings, Inc., a Delaware corporation (the “Seller Subsidiary,” and together with the Parent, the “Sellers”), and Crealta Pharmaceuticals LLC, a Delaware limited liability company (the “Purchaser”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in Article IX.
Amendment to Employment AgreementAmendment to Employment Agreement • March 31st, 2003 • Bio Technology General Corp • Medicinal chemicals & botanical products
This Amendment is made, entered into, and is effective as of the Amendment Date, by and between the Company and the Executive.
AMENDED AND RESTATED EMPLOYMENT AND CONFIDENTIALITY AGREEMENTEmployment and Confidentiality Agreement • February 19th, 2009 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New Jersey
This Employment and Confidentiality Agreement (this “Agreement”) is entered into as of February 6, 2006, and amended and restated as of February 12, 2009, by and among David G. Gionco (“Employee”) and Savient Pharmaceuticals, Inc., a Delaware corporation having an address of One Tower Center, 14th Floor, East Brunswick, NJ 08816 (the “Company”).
Execution CopySeparation and General Release Agreement • June 2nd, 2011 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New Jersey
This Agreement must be executed and delivered to the Company (Attn: Philip K. Yachmetz, Senior Vice President & General Counsel) on or before June 21, 2011, but not prior to May 30, 2011.
CONSULTING SERVICES AGREEMENT BETWEEN SAVIENT PHARMACEUTICALS, INC. ANDConsulting Services Agreement • May 8th, 2009 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New Jersey
THIS CONSULTING SERVICES AGREEMENT (hereinafter referred to as the “Agreement”) effective as of the 22nd day of January, 2009 by and between Savient Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware with a place of business at One Tower Center, East Brunswick, New Jersey 08816 (hereinafter referred to as “Company”), and Lee S. Simon, MD (hereinafter referred to as “Consultant”).
EXHIBIT 10.2 UNLIMITED GUARANTY In consideration of financial accommodations given or to be given or continued to Bio-Technology General (Israel) Ltd., herein called "Borrower" by BANK HAPOALIM B.M., having branch offices outside the United States,...Bio Technology General Corp • August 14th, 2000 • Medicinal chemicals & botanical products
SHARE PURCHASE AGREEMENT relating to ROSEMONT PHARMACEUTICALS LIMITED between NED-INT HOLDINGS LTD and AKZO NOBEL N.V. on the one side BIO-TECHNOLOGY GENERAL CORP. on the other sideShare Purchase Agreement • October 15th, 2002 • Bio Technology General Corp • Medicinal chemicals & botanical products
BIO-TECHNOLOGY GENERAL CORP. whose registered office is at 70 Wood Avenue South, Iselin, New Jersey 08830, USA or such other of its Affiliates from time to time as it may nominate pursuant to Clause 9.6 (the Purchaser).
SAVIENT PHARMACEUTICALS, INC. Underwriting AgreementSavient Pharmaceuticals Inc • February 1st, 2011 • Medicinal chemicals & botanical products • New York
Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $200,000,000 principal amount of its 4.75% Convertible Senior Notes due 2018 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $30,000,000 principal amount of its 4.75% Convertible Senior Notes due 2018 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 4.75% Convertible Senior Notes due 2018 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per share (the “Common Stock”). The Securities will be issued pursuant
EMPLOYMENT AGREEMENTEmployment Agreement • August 10th, 2001 • Bio Technology General Corp • Medicinal chemicals & botanical products • New Jersey
AGREEMENT made as of June 4, 2001, between BIO-TECHNOLOGY GENERAL CORP., a Delaware corporation with an office at 70 Wood Avenue South, Iselin, New Jersey 08830 (the "Company") and John A. Bond, having a residence at 130 Colket Lane, Devon, PA 19333 (the "Executive").
SUBSCRIPTION AGREEMENTSubscription Agreement • April 3rd, 2009 • Savient Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
The undersigned (the “Investor”) hereby confirms its agreement with Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), as follows:
